Melanoma vaccine reduces death or cancer recurrence by 42%
In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient's own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests
United Kingdom
-
US–Mexico border counties face high kidney disease–related mortality and low nephrologist availability
United Kingdom
-
Standard kidney function tests underestimate chronic kidney disease in people with cancer
United Kingdom
-
5 great cardio workouts you can do at home
United Kingdom
-
Online resources and coaching helped people seek genetic testing for cancer
United Kingdom
-
Study identifies potential new treatment targets for the most common type of bowel cancer
United Kingdom
-
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
United Kingdom
-
A third of young adults turn to AI for substance-use information
United Kingdom